Aarti Industries Ltd: India's NCB Specialty Chemicals Leader Navigating Margin Recovery and Debt-Fueled Expansion

NSE: AARTIIND | BSE: 2412 | Sector: Chemicals | CMP: ₹475 | Market Cap: ₹17,223 Cr

Business Overview

Aarti Industries Ltd is the flagship company of the Aarti Group, one of India's largest and most diversified specialty chemical manufacturers. Founded and headquartered in Gujarat, the company operates major manufacturing facilities at Vapi, Jhagadia, Dahej, Kutch (all in Gujarat), and Tarapur (Maharashtra). The company has established a formidable market position in the Nitro Chloro Benzene (NCB)-based specialty chemicals segment, which serves as the backbone of its integrated product portfolio spanning multiple high-growth end-use industries.

The company's business spans seven distinct verticals: specialty chemicals, agrochemicals and fertilizers, dyes, pigments and printing inks, pharmaceutical intermediates, polymer and additives, energy-related chemicals, and other specialty applications. This diversified presence provides Aarti Industries with multiple growth levers and reduces dependence on any single end-market, though agrochemicals and pharmaceutical intermediates remain the dominant revenue contributors.

Aarti Industries' competitive moat lies in its backward-integrated manufacturing approach. The company is the world's largest producer of NCB, with a strong presence in downstream derivatives like Mono Methyl Aniline (MMA), Di Chloro Benzene (DCB), and Nitro Toluene (NT). This integration provides cost advantages, supply security for customers, and high switching costs that protect market share. The company also has a significant presence in the ethylation product line, further deepening its chemical value chain.

With a product portfolio exceeding 200+ specialty chemicals and customers spanning over 60 countries, Aarti Industries has positioned itself as a critical link in the global specialty chemicals supply chain. The company counts leading multinational agrochemical, pharmaceutical, and polymer companies among its long-standing clients, with many relationships spanning decades. Key customers include major global agrochemical players who rely on Aarti for critical intermediates that go into crop protection formulations.

The company has been on a significant capacity expansion trajectory, with capital work-in-progress (CWIP) rising from ₹193 Cr in FY2015 to ₹2,030 Cr in FY2026 — a more than 10x increase over a decade. This expansion is focused on debottlenecking existing plants, expanding derivative capacities, and entering new product lines in higher-margin specialty chemical segments. The capex cycle, which peaked in recent years, is expected to gradually moderate as new capacities come on-stream and begin contributing to revenues.

However, this aggressive expansion has come at a cost. The company's borrowings have surged from ₹1,202 Cr in FY2015 to ₹4,966 Cr in FY2026, resulting in a Debt-to-Equity ratio of approximately 0.78x at the consolidated level. The interest burden has grown commensurately, from ₹138 Cr in FY2015 to ₹340 Cr in FY2026 — a 146% increase that has significantly compressed profitability metrics despite top-line growth.

The current market capitalization of ₹17,223 Cr values the company at a P/E of 41.8x on trailing twelve-month earnings, which appears elevated relative to its current ROE of 7.13% and ROCE of 6.85%. The stock trades at 2.89x its book value of ₹164 per share, and the 52-week trading range of ₹338 to ₹523 indicates significant volatility. At the CMP of ₹475, the stock is approximately 9.2% below its 52-week high and 40.5% above its 52-week low.

Latest Quarter Deep Dive (Q4 FY2026 — March 2026)

The latest reported quarter — Q4 FY2026 (March 2026) — delivered a mixed set of results that reflected both the benefits of capacity ramp-up and the continued drag from elevated interest costs and depreciation charges associated with the expansion programme.

Revenue Performance

Quarterly revenue for Q4 FY2026 came in at ₹2,205 Cr, representing a 13.13% YoY growth from ₹1,949 Cr in Q4 FY2025. However, this was a sequential decline from the ₹2,318 Cr reported in Q3 FY2026 (December 2025), indicating some seasonality or order timing effects. The full-year FY2026 revenue stood at ₹8,286 Cr, up 14% YoY from ₹7,271 Cr in FY2025 — a clear indication that the company's top-line trajectory remains healthy despite broader macro headwinds in the specialty chemicals sector.

The quarterly sales progression over the last four quarters shows: ₹1,675 Cr (Q1 FY2026), ₹2,100 Cr (Q2 FY2026), ₹2,318 Cr (Q3 FY2026), and ₹2,205 Cr (Q4 FY2026). The TTM (Trailing Twelve Months) revenue stands at approximately ₹8,298 Cr, indicating stable demand across key end-markets.

Operating Profitability

Operating profit for Q4 FY2026 was ₹341 Cr, translating to an OPM of 15% — the highest quarterly operating margin in FY2026 and a meaningful improvement from the 13% OPM seen in Q1 and Q2 of the fiscal year. This margin expansion is significant as it suggests that operating leverage is beginning to kick in as new capacities ramp up.

However, the OPM trajectory needs to be viewed in the context of a longer-term decline. From a peak of 28% OPM in FY2022 (driven by exceptional pricing power during the post-COVID chemical supercycle), margins have contracted to 14-15% levels — a 13-14 percentage point compression that reflects normalization of chemical prices, rising raw material costs, and the initial dilutive impact of new capacity additions that are yet to reach optimal utilization.

The quarterly OPM progression over the last 13 quarters tells the margin recovery story:

The recovery from the 12% trough in September 2024 to 15% by March 2026 is encouraging, though margins remain well below the 22-28% levels seen in FY2021-FY2022.

Profitability at the Net Level

Net profit for Q4 FY2026 was ₹137 Cr, a 42.71% YoY increase from ₹96 Cr in Q4 FY2025. The EPS for the quarter was ₹3.78, up from ₹2.65 in Q4 FY2025. However, a significant portion of the reported "profit" benefit comes from negative tax rates — the effective tax rate for Q4 FY2026 was -23%, meaning the company received a net tax credit rather than paying taxes. This pattern of negative/low tax rates has been persistent across recent quarters:

The consistently negative tax rates suggest significant deferred tax asset creation or tax incentives related to the company's manufacturing units in SEZ/specified zones. While this benefits reported earnings, it introduces an element of risk if these tax benefits were to normalize — the PBT of ₹111 Cr in Q4 FY2026 would have translated to a materially lower net profit under a standard 25% tax rate (approximately ₹83 Cr).

Key Expense Head Analysis

Raw material and operating expenses for Q4 FY2026 stood at ₹1,864 Cr, consuming 84.5% of revenues — relatively stable compared to prior quarters. Interest costs for the quarter were ₹112 Cr, the highest quarterly interest outgo in the last 13 quarters, reflecting the full-year impact of the ₹4,966 Cr gross borrowings. Depreciation was ₹119 Cr, broadly in line with the ₹114-121 Cr range seen over the prior three quarters.

The combined interest and depreciation burden of ₹231 Cr in Q4 FY2026 consumed 10.5% of quarterly revenue, compared to just 6.9% in Q4 FY2023 (₹117 Cr combined on ₹1,656 Cr revenue) — a significant structural increase in fixed charges that caps bottom-line growth.

Quarterly Results Summary Table

5-Year Profit & Loss Analysis (FY2022 — FY2026)

The five-year financial trajectory of Aarti Industries provides a nuanced picture of a company that experienced a windfall cycle in FY2022 and has since been working through a normalization phase, while simultaneously investing heavily in future growth capacity.

Revenue Growth Trajectory

The 5-year CAGR in revenue stands at 8% (3-year), but more meaningfully at 11% on a 10-year basis and 13% on a 5-year compounded basis. The TTM revenue growth of 14% indicates that the company has successfully navigated the post-super-cycle slowdown and is now growing at a healthy double-digit clip, supported by new capacity additions and deepening customer relationships.

The FY2024 revenue dip of 3.7% (from ₹6,619 Cr to ₹6,371 Cr) was the only year of negative revenue growth in the 5-year window, driven by destocking in agrochemical channels and pricing headwinds in select product lines. The sharp recovery in FY2025 and FY2026 demonstrates the resilience of the underlying demand drivers.

Operating Profit and Margin Compression

This is the most concerning aspect of Aarti Industries' financial performance. Operating profit has declined from the ₹1,720 Cr peak in FY2022 to ₹1,167 Cr in FY2026 — a 32% decline despite revenues growing by 36% over the same period. The OPM compression from 28% to 14% — a 14 percentage point decline — is dramatic and reflects:

1. Normalization of chemical prices from the COVID-era supply chain disruption windfall
2. Rising raw material costs and competitive pricing pressure
3. Initial dilution from new capacity additions that are yet to reach optimal utilization and margins
4. Increased employee and overhead costs associated with expanded operations

The positive takeaway is that FY2026 operating profit of ₹1,167 Cr represents a 16.7% YoY increase from FY2025's ₹1,000 Cr, suggesting that the margin trough may be behind us.

Net Profit and EPS Trajectory

Net profit has declined by 64.7% from the FY2022 peak of ₹1,186 Cr to FY2025's ₹331 Cr, before recovering to ₹419 Cr in FY2026. The 5-year profit CAGR of -5% and 3-year profit CAGR of -9% stand in stark contrast to the healthy revenue growth, underscoring the severity of the margin and cost headwinds.

Importantly, the TTM profit growth of 25% signals a turning point. If the company can sustain its Q4 FY2026 level of profitability (₹137 Cr quarterly), the annualized run-rate would be approximately ₹548 Cr — which would represent a meaningful recovery.

A critical factor propping up reported net profit is the persistently negative tax rate. Over the last 5 years, the effective tax rate has been: 14% (FY2022), 11% (FY2023), -5% (FY2024), -8% (FY2025), and -15% (FY2026). Under a normalized 25% tax rate, FY2026's PBT of ₹365 Cr would translate to approximately ₹274 Cr net profit — significantly below the reported ₹419 Cr. This is a key risk factor for reported earnings quality.

Expense Structure Evolution

The operating expense ratio has increased from 71.7% in FY2022 to 85.9% in FY2026, reflecting the margin compression discussed above. Meanwhile, interest costs have more than tripled from ₹102 Cr to ₹340 Cr (a 233% increase), and depreciation has nearly doubled from ₹246 Cr to ₹474 Cr (a 93% increase) — both consequences of the aggressive capex programme.

Dividend History

The company's dividend payout has been conservative:

The current dividend yield of 0.21% offers negligible income. The low payout is understandable given the capital-intensive expansion phase, but it means investors are entirely dependent on capital appreciation for returns.

Compounded Growth Summary

The stark divergence between 13% 5-year sales growth and -5% 5-year profit growth captures the essence of Aarti Industries' recent financial story — a company growing its topline impressively while its bottom-line has deteriorated due to structural margin compression and rising financial costs. The stock's -9% CAGR over 5 years reflects this disconnect.

Balance Sheet Analysis (FY2022 — FY2026)

Asset Growth and Capital Employed

The balance sheet tells the story of aggressive capacity building:

Total assets have grown by 69.4% from ₹7,851 Cr to ₹13,299 Cr over five years. The fixed asset base (including CWIP) stands at ₹8,586 Cr in FY2026, comprising 64.6% of total assets — a capital-intensive profile typical of chemical manufacturing.

The CWIP of ₹2,030 Cr in FY2026 is significant and represents ongoing expansion projects. As these assets get commissioned and move to the fixed asset category, they should begin contributing to revenues and operating profits. However, until they reach optimal utilization, they will continue to add to depreciation charges without proportionate revenue contribution.

Liabilities and Leverage

Key leverage metrics:

• Debt-to-Equity Ratio (FY2026): Borrowings ₹4,966 Cr / (Equity + Reserves = ₹5,955 Cr) = 0.83x
• Total Debt grew by 92% from ₹2,587 Cr (FY2022) to ₹4,966 Cr (FY2026)
• Net Worth (Equity + Reserves) grew by 37% from ₹4,516 Cr to ₹5,955 Cr over the same period
• Interest Coverage Ratio (FY2026): Operating Profit ₹1,167 Cr / Interest ₹340 Cr = 3.4x — adequate but has deteriorated from 16.9x in FY2022

The borrowings trajectory is concerning — from ₹2,587 Cr to ₹4,966 Cr in just four years, a 92% increase. The interest coverage ratio, while still adequate at 3.4x, has declined sharply from the comfortable 16.9x in FY2022. If operating profits were to weaken further, the interest burden could become a more pressing concern.

Shareholder Funds and Book Value

The book value per share stands at ₹164 (as reported by Screener.in), implying a Price-to-Book ratio of 2.89x at the CMP of ₹475. Given the current ROE of just 7.13%, the premium over book value appears stretched, as investors are paying nearly 3x book value for a business earning a sub-10% return on equity.

Cash Flow Analysis (FY2022 — FY2026)

Cash Flow Quality

The most important takeaway from the cash flow statement is that Aarti Industries has not generated positive free cash flow in any of the last five years. Free cash flow has been negative throughout: -₹646 Cr (FY2022), -₹8 Cr (FY2023), -₹96 Cr (FY2024), -₹137 Cr (FY2025), and -₹346 Cr (FY2026).

This persistent negative FCF is a direct consequence of the heavy capital expenditure programme. While Cash from Operations (CFO) has been reasonably strong at ₹775-₹1,319 Cr annually, it has been insufficient to fund the ₹1,141-₹1,398 Cr annual capital expenditure. The gap has been filled by debt — as evidenced by the ₹745 Cr net financing inflow in FY2026.

The CFO-to-Operating Profit ratio averaged 119% over FY2022-FY2025 (excluding the anomalous FY2022 figure of 44%), indicating good cash conversion from reported profits. However, the FY2026 figure of 67% is concerning and warrants monitoring — it could indicate working capital pressure or one-off timing effects.

Working Capital Efficiency

The cash conversion cycle has improved dramatically from 155 days in FY2022 to 54 days in FY2026 — a 65% improvement driven primarily by better payable management (days payable increased from 53 to 126). The negative working capital days of -64 in FY2026 indicate that the company's current liabilities exceed its current assets excluding cash — effectively funding part of its operations through supplier credit.

However, the increase in debtor days from 39 (FY2025) to 62 (FY2026) is a yellow flag, as it suggests lengthening collection cycles from customers. This trend needs monitoring as it could indicate either customer stress or competitive pressure requiring more generous credit terms.

Peer Comparison

Aarti Industries operates in the highly competitive Indian specialty chemicals sector. Here is how it compares with key listed peers:

Key Peer Observations

1. ROCE Gap: Aarti Industries' ROCE of 6.85% is the lowest among its listed specialty chemical peers and well below the sector median of 14.57%. Compare this with Pidilite's 30.97%, Navin Fluorine's 21.37%, or even Deepak Nitrite's 11.49%. This sub-par capital efficiency is a fundamental concern and reflects the heavy capital employed in ongoing expansion projects that have yet to generate proportional returns.

2. Valuation Premium Despite Inferior Returns: At a P/E of 41.80x, Aarti Industries trades at a 43% premium to the sector median P/E of 29.11x, despite having the lowest ROCE in the peer set. This implies that the market is pricing in a significant improvement in profitability as new capacities ramp up. If this improvement fails to materialize, the stock faces meaningful downside risk.

3. Revenue Scale Advantage: With quarterly sales of ₹2,205 Cr, Aarti Industries has the highest quarterly revenue among its closest peers, surpassing even Pidilite's ₹3,583 Cr (though Pidilite operates in a different product segment with much higher margins). This scale provides cost advantages and customer stickiness.

4. Profit Growth Momentum: The 42.71% QoQ profit growth in the latest quarter is encouraging and better than Gujarat Fluorochem (-41.93%) and Anupam Rasayan (-4.31%), though below Navin Fluorine's exceptional 113.03% growth.

5. Valuation vs. Deepak Nitrite: The most direct comparable — Deepak Nitrite — trades at 40.98x P/E (similar to Aarti's 41.80x) but delivers a much superior ROCE of 11.49% (vs. 6.85%). This suggests Aarti may be overvalued relative to its closest peer on a capital efficiency basis.

DCF Valuation Framework

Assumptions

Given the heavy capex cycle and margin compression, a DCF model for Aarti Industries requires careful consideration of the following:

Base Case Assumptions:

• Revenue Growth: 12% CAGR for years 1-5 (driven by capacity ramp-up), moderating to 8% CAGR for years 6-10
• Terminal Growth Rate: 5% (long-term GDP growth)
• Steady-State Operating Margin: 16% (mid-cycle recovery from current 14%, but below the 22-28% peak)
• Effective Tax Rate: 20% (normalized, assuming partial continuation of incentives)
• WACC: 11% (reflecting India's risk premium and the company's leverage)
• Capex-to-Sales Ratio: Gradually declining from 14% to 8% as expansion moderates

Key Valuation Outputs

Free Cash Flow to Firm (FCFF) Projections:

At steady state with ₹8,286 Cr base revenue, 12% growth, and 16% operating margins:

• Year 1 FCFF estimate: approximately ₹250-300 Cr (reflecting continued high capex)
• Year 5 FCFF estimate: approximately ₹600-700 Cr (as capex normalizes)
• Year 10 FCFF estimate: approximately ₹1,000-1,200 Cr (mature state)

Implied Valuation Range:

Valuation Assessment

At the current CMP of ₹475, the stock appears to be fairly valued in the base case scenario, assuming the company successfully achieves:

• Revenue growth of 12% CAGR over the next 5 years
• Operating margin recovery to 16% (from current 14%)
• Gradual moderation of capex intensity
• Effective tax rate remaining below the statutory 25%

The bull case valuation of ₹660-770 would require operating margins to recover to 18-20% levels — possible if new capacities achieve higher utilization and product mix improves. The bear case of ₹330-385 represents the scenario where margins remain depressed at 12-13% and capex remains elevated for longer.

Alternative: Earnings-Based Valuation

On a trailing basis with EPS of ₹11.56 and P/E of 41.8x:

• The stock is already priced for significant earnings growth
• If EPS can grow to ₹20-25 over the next 3-4 years (through margin recovery and revenue growth), the current price offers 40-55% upside
• If earnings stagnate or decline further, the 41.8x P/E offers little downside protection

Key sensitivity: A 1 percentage point change in operating margin impacts annual operating profit by approximately ₹83 Cr (1% of ₹8,286 Cr revenue), which at a 30x P/E translates to roughly ₹68 per share of valuation impact.

Key Risks

1. Margin Recovery Failure

The single biggest risk to the investment thesis is that operating margins may fail to recover from the current 14-15% levels. If competitive intensity in specialty chemicals continues to increase, or if global chemical prices remain subdued, margins could remain range-bound at 12-15%, making the current valuation unsustainable.

2. Elevated Leverage and Interest Burden

With ₹4,966 Cr in borrowings and interest costs at ₹340 Cr (and rising), any prolonged weakness in operating profits could strain the balance sheet. The interest coverage ratio of 3.4x provides a buffer, but further debt addition without proportional profit growth could erode this cushion. The ₹2,030 Cr CWIP suggests additional borrowing may be needed if internal accruals are insufficient.

3. Tax Rate Normalization

The persistent negative effective tax rates (-8% to -23% in recent quarters) are unsustainable in the long run. If the company's SEZ/incentive benefits phase out and the effective tax rate normalizes to 20-25%, reported net profit would take a 20-35% hit, dramatically altering the P/E calculus.

4. Customer Concentration and Agrochemical Cycle

A significant portion of Aarti's revenue is tied to the agrochemical cycle, which is inherently volatile. Any adverse weather patterns, regulatory changes in key markets (EU, US, Brazil), or shifts in crop protection chemistry could impact demand for the company's intermediates.

5. Working Capital Deterioration

The increase in debtor days from 39 to 62 in FY2026 signals potential collection challenges. If this trend worsens, it could further strain cash flows and necessitate additional borrowing.

6. Capitalization of Interest Costs

Screener.in's automated analysis flags that "Company might be capitalizing the interest cost." This is consistent with the heavy CWIP figure and suggests that some interest costs may be getting added to the cost of assets rather than flowing through the P&L. If true, the actual economic cost of debt is higher than what the reported interest expense suggests.

7. Promoter Stake Decline

Promoter holding has declined from 53.78% in FY2017 to 42.09% in FY2026 — a 11.69 percentage point reduction over a decade. While partially offset by increasing DII holdings (12.08% to 20.12%), the declining promoter stake raises questions about long-term alignment of interests.

8. Global Competition

Indian specialty chemical companies face increasing competition from Chinese suppliers who have been regaining competitiveness as domestic energy and raw material costs stabilize. Any aggressive pricing by Chinese competitors could further pressure Aarti's margins.

9. Subsidiary Performance

Consolidated numbers include subsidiary performance, and any underperformance in subsidiary operations could impact overall financials. The detailed segment-level data is not readily available on Screener without login.

10. FII Exit Risk

FII holdings have declined from a peak of 12.46% (FY2022) to 7.38% (FY2026), with a low of 6.29% in FY2025. While the recent uptick to 7.38% is positive, any further FII exit could create selling pressure, especially in a small-cap/mid-cap stock with relatively lower liquidity.

Investment Thesis

The Bull Case (Target: ₹600-700 / 25-45% upside from CMP ₹475)

1. Inflection Point in Profitability: FY2026 marks the first year of profit growth (+26.6% YoY) after three consecutive years of decline. The TTM profit growth of 25% and improving quarterly trends suggest the earnings trough is behind us. If the company sustains its Q4 FY2026 net profit run-rate of ₹137 Cr per quarter (annualized ₹548 Cr), the stock trades at a more reasonable 31x forward P/E.

2. Capacity Coming On-Stream: The ₹2,030 Cr CWIP represents future revenue-generating capacity. As these assets get commissioned and ramp up utilization over the next 2-3 years, they should drive both top-line growth and operating leverage. The company's integrated manufacturing model means new capacity typically generates returns above the corporate average once mature.

3. Operating Margin Recovery Potential: The OPM has improved from the 12% trough (Sep 2024) to 15% (Mar 2026). If the company can get back to even 17-18% operating margins (vs. the historical peak of 28%), the earnings uplift would be substantial. Each 1 percentage point of margin improvement adds approximately ₹83 Cr to operating profit.

4. Structural Tailwinds for Indian Specialty Chemicals: The "China+1" sourcing strategy adopted by global chemical majors provides a multi-year demand tailwind for Indian manufacturers. Aarti Industries, with its scale, integration, and established customer relationships, is well-positioned to capture this shift.

5. Strong Cash Generation (Despite Negative FCF): The CFO has averaged ₹1,100+ Cr annually over the last 4 years (excluding FY2022's anomalous ₹519 Cr), demonstrating strong underlying cash generation capability. Once capex moderates, the FCF inflection could be dramatic.

The Bear Case (Target: ₹300-380 / 20-37% downside from CMP ₹475)

1. Valuation Disconnect: At 41.8x P/E and 2.89x P/B, the stock is priced for a recovery that may take longer than expected. The ROE of 7.13% and ROCE of 6.85% are deeply inadequate for the premium valuation — paying 3x book value for a business earning 7% on equity creates negative economic value.

2. Debt Overhang: The ₹4,966 Cr in borrowings and rising interest costs (₹340 Cr in FY2026) mean that even moderate growth disappointments could trigger a debt spiral. If operating margins remain at 13-14% and capex continues, the company may need additional equity dilution to manage its balance sheet.

3. Earnings Quality Concerns: The reliance on negative tax rates to boost reported earnings is a structural concern. Normalization of tax rates to 20-25% could reduce reported EPS by 25-35%, making the stock significantly more expensive on a tax-adjusted basis.

4. Historical Destruction of Value: The stock's -9% CAGR over 5 years (from much higher levels in 2021) is a reminder that momentum in specialty chemicals can reverse sharply. The ₹1,720 Cr peak operating profit in FY2022 remains unmatched, and investors who bought at the peak have lost substantial capital.

Our Assessment

Aarti Industries is at an inflection point — the worst of the margin compression appears to be behind, revenue growth is healthy at 14% YoY, and the capacity pipeline is robust. However, the stock's 41.8x P/E bakes in significant recovery expectations, leaving limited margin of safety if the turnaround disappoints.

The key monitorables for investors over the next 2-3 quarters are:

1. Operating margin trajectory — sustained improvement above 15% is critical
2. Interest cost trajectory — any moderation would be a significant positive
3. CWIP commissioning schedule — new capacity contributing to revenue
4. Tax rate normalization — the timing and extent of this risk
5. Debtor days — whether the FY2026 spike to 62 days is temporary or structural

Risk-Reward Verdict: The stock offers a moderately attractive risk-reward for investors with a 3-4 year horizon who believe in the structural India specialty chemicals story and are willing to tolerate near-term earnings volatility. However, the elevated valuation relative to current returns on capital means this is not a value pick — it is a growth-at-reasonable-price (GARP) bet that requires execution to play out. We would recommend waiting for a pullback to the ₹380-420 range for a more favorable entry point, where the downside risk is better compensated.

Shareholding Pattern Analysis

Promoter Holding Trend

Promoter holding has declined by 11.69 percentage points over a decade — from 53.78% to 42.09%. While this partly reflects equity issuances for capex funding, the consistent downward trend warrants monitoring. However, the promoter holding remains above 40%, which is generally considered a comfortable threshold for alignment of interests.

Institutional Holdings

Key observations:

• FII holding has nearly halved from 12.17% (Jun 2023) to 7.38% (Mar 2026), though the recent uptick from 6.29% (Mar 2025) is encouraging
• DII holding has increased from 14.83% to 20.12%, suggesting domestic institutional investors (mutual funds, insurance companies) see value at current levels
• Retail/public holding remains stable at 30-33%, indicating continued retail interest
• Number of shareholders has declined from 4,50,588 (Dec 2024) to 3,84,210 (Mar 2026), suggesting some retail consolidation

Shareholding Verdict

The increasing DII allocation is a positive signal — it suggests that sophisticated domestic institutional investors are building positions, likely anticipating the margin recovery thesis. However, the declining FII presence indicates that foreign investors are less convinced or are reallocating to other Indian chemical plays with better current profitability metrics.

Final Summary

Aarti Industries Ltd is a high-quality specialty chemical franchise with strong market positions, integrated manufacturing capabilities, and a robust capacity pipeline. The company's 14% TTM revenue growth and 25% TTM profit growth suggest the worst is behind, and the ₹2,030 Cr CWIP provides visibility on future growth.

However, the 41.8x P/E valuation demands near-flawless execution on margin recovery, capex commissioning, and debt management. The 6.85% ROCE and 7.13% ROE are inadequate for the premium valuation, and the negative effective tax rates inflate reported earnings.

For long-term investors (3-4 year horizon): Accumulate on dips towards ₹380-420 for a target of ₹600-700.

For short-term traders: The stock may face near-term headwinds at ₹475 given the elevated valuation and potential tax normalization risk. Await a clearer margin recovery signal.

Key Financial Snapshot:

• CMP: ₹475 | Market Cap: ₹17,223 Cr | P/E: 41.8x | P/B: 2.89x
• ROCE: 6.85% | ROE: 7.13% | Div Yield: 0.21%
• Debt/Equity: 0.83x | Interest Coverage: 3.4x
• FY2026 Revenue: ₹8,286 Cr | FY2026 Net Profit: ₹419 Cr | FY2026 EPS: ₹11.56
• 52-Week Range: ₹338 — ₹523 | Face Value: ₹5.00

Data Source: Screener.in (Consolidated Financials). All financial figures in ₹ Crores unless stated otherwise. Data as of May 29, 2026. This article is for informational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making investment decisions.